314 related articles for article (PubMed ID: 22227958)
1. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.
Stangier J; Feuring M
Blood Coagul Fibrinolysis; 2012 Mar; 23(2):138-43. PubMed ID: 22227958
[TBL] [Abstract][Full Text] [Related]
2. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Hapgood G; Butler J; Malan E; Chunilal S; Tran H
Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
[TBL] [Abstract][Full Text] [Related]
3. Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis.
Schmohl M; Gansser D; Moschetti V; Stangier J
Thromb Res; 2015 Mar; 135(3):532-6. PubMed ID: 25600440
[TBL] [Abstract][Full Text] [Related]
4. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay.
Gosselin RC; Dwyre DM; Dager WE
Ann Pharmacother; 2013 Dec; 47(12):1635-40. PubMed ID: 24259624
[TBL] [Abstract][Full Text] [Related]
5. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
[TBL] [Abstract][Full Text] [Related]
6. On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
Skeppholm M; Hjemdahl P; Antovic JP; Muhrbeck J; Eintrei J; Rönquist-Nii Y; Pohanka A; Beck O; Malmström RE
Thromb Res; 2014 Oct; 134(4):783-9. PubMed ID: 25172669
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
Wong PC; White A; Luettgen J
Hosp Pract (1995); 2013 Feb; 41(1):19-25. PubMed ID: 23466964
[TBL] [Abstract][Full Text] [Related]
8. In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban.
He S; Wallèn H; Bark N; Blombäck M
J Thromb Thrombolysis; 2013 Feb; 35(2):131-9. PubMed ID: 22843196
[TBL] [Abstract][Full Text] [Related]
9. UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma.
Delavenne X; Moracchini J; Laporte S; Mismetti P; Basset T
J Pharm Biomed Anal; 2012 Jan; 58():152-6. PubMed ID: 21996066
[TBL] [Abstract][Full Text] [Related]
10. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.
van Ryn J; Grottke O; Spronk H
Clin Lab Med; 2014 Sep; 34(3):479-501. PubMed ID: 25168938
[TBL] [Abstract][Full Text] [Related]
11. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Hawes EM; Deal AM; Funk-Adcock D; Gosselin R; Jeanneret C; Cook AM; Taylor JM; Whinna HC; Winkler AM; Moll S
J Thromb Haemost; 2013 Aug; 11(8):1493-502. PubMed ID: 23718677
[TBL] [Abstract][Full Text] [Related]
12. Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
Okubo K; Kuwahara T; Takagi K; Takigawa M; Nakajima J; Watari Y; Nakashima E; Yamao K; Fujino T; Tsutsui H; Takahashi A
Am J Cardiol; 2015 Jun; 115(12):1696-9. PubMed ID: 25918026
[TBL] [Abstract][Full Text] [Related]
13. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran assessment in patients with acute complications using routine coagulation assays.
Stang L; Nahirniak S; Butcher K; Szkotak AJ
Blood Coagul Fibrinolysis; 2014 Jul; 25(5):426-34. PubMed ID: 24637695
[TBL] [Abstract][Full Text] [Related]
15. Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatran.
Stief TW
Blood Coagul Fibrinolysis; 2012 Oct; 23(7):619-21. PubMed ID: 22821003
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Li YZ; Gong GQ; Yang WH; Wang XH; Jiang ML; Zhou Y; Yang XZ; Xu YG; He GW
Thromb Res; 2013 May; 131(5):425-35. PubMed ID: 23535565
[TBL] [Abstract][Full Text] [Related]
17. The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters.
Green L; Lawrie AS; Patel R; Stephens RC; Mackie IJ; Chitolie A; Haddad FS; Machin SJ
Thromb Res; 2012 Nov; 130(5):775-9. PubMed ID: 22245224
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran: is there a role for coagulation assays in guiding therapy?
Brunetti L; Bandali F
Ann Pharmacother; 2013 Jun; 47(6):828-40. PubMed ID: 23673530
[TBL] [Abstract][Full Text] [Related]
19. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice.
Lee IO; Kratz MT; Schirmer SH; Baumhäkel M; Böhm M
J Pharmacol Exp Ther; 2012 Nov; 343(2):253-7. PubMed ID: 22837011
[TBL] [Abstract][Full Text] [Related]
20. Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses: a prospective study based on peak and trough plasma levels.
Gosselin R; Hawes E; Moll S; Adcock D
Am J Clin Pathol; 2014 Feb; 141(2):262-7. PubMed ID: 24436275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
